3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Breast
1
Conditions
Glioma
3
Glioblastoma
3
Lung Neoplasms
2
Astrocytoma
2
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Mesothelioma
1
Ependymoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Paclitaxel
81
Trastuzumab
76
Fulvestrant
55
Cyclophosphamide
49
Capecitabine
42
Lapatinib
40
pembrolizumab
38
Docetaxel
38
palbociclib
36
Carboplatin
32
Letrozole
28
olaparib
23
Doxorubicin
23
Gemcitabine
21
Taxes
20
Everolimus
20
ribociclib
19
abemaciclib
19
Ado-Trastuzumab Emtansine
18
pertuzumab
17
Radiotherapy
17
Magnetic Resonance Spectroscopy
17
Bevacizumab
16
130-nm albumin-bound paclitaxel
16
exemestane
15
Vinorelbine
15
Cisplatin
15
veliparib
14
Biopsy
14
Alpelisib
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Breast Neoplasms
×
Valacyclovir
×
Clear all
NCT01997190
2023-08-25
MpeTK01
Candel Therapeutics, Inc.
Phase 1
Completed
19 enrolled